深度医疗

Proprio, founded in 2016 and headquartered in Seattle, develops an AI-powered surgical platform. Its flagship product, Paradigm, has received FDA 510(k) clearance and is designed to improve surgical precision and efficiency.

Series B · $43M · 2023-08

Overture Life, founded in 2017 in Palo Alto, develops robotic devices that automate the handling and preparation of eggs and embryos for in vitro fertilization.

Undisclosed · $21M · 2025-04

Dopl Technologies develops a hardware-agnostic teleoperated robotic ultrasound platform that lets remote sonographers perform diagnostic ultrasound exams for patients in rural and workforce-limited areas; its products include Traverse (telerobotic ultrasound), Dopl Connect and SonoFlex, and it is advancing toward FDA clearance. Based in Bothell (Seattle), Washington, founded 2022.

Seed · $8M · 2026-07

Shanghai Sibo Huiyi Technology develops a fully automatic magnetically controlled interventional surgery robot platform for cerebrovascular procedures, driven by a vision-language-action (VLA) foundation model trained via self-reinforcement learning in a physics-simulation world model, with 4D-DSA digital-twin hardware.

Series A · 2026-09

Pangce Medical (磅策医疗), founded in Shanghai, China in 2019, is a developer of medical surgical robots focused on core technologies including orthopedic and surgical robots and navigation positioning. The current funding round will be used for core technology iteration, new product pipeline R&D and clinical registration, commercialization channel expansion, and global market development.

Series B · $15M · 2026-04

Shenzhen Ruixin Intelligent Medical Technology Co., Ltd., founded in December 2017 by three returnee PhDs — Zheng Lingxiao, Lan Hongzhi, and Ma Jun — develops an AI and surgical robotics precision diagnosis and treatment platform for cardiovascular and cerebrovascular diseases. Core products include Ruixin Score (CT-FFR non-invasive coronary functional assessment), AngioQFA coronary functional measurement system, and intracardiac ultrasound, with an AI vascular interventional surgical robot under development; the company holds 11 NMPA registration certificates and EU CE certification, with clinical partnerships at over 800 hospitals.

Strategic · 2026-07

Nami Surgical, founded in 2021 in Glasgow, Scotland, develops miniaturized ultrasonic medical devices for surgical applications, including high-performance compact ultrasonic scalpels designed to overcome limitations in robot-assisted surgery.

Undisclosed · $4M · 2024-05

XRlabs (incorporated as SIMXAR LTD in January 2024, renamed in August 2025) is a London-headquartered surgical intelligence company with a Palo Alto office, founded by neurosurgeon Ali Haddad, embedding AI, computer vision and XR into operating-room equipment for surgical planning, training and real-time intraoperative guidance.

Seed · 2026-10

Hypervision Surgical, founded in 2020 in London, UK, is a surgical intelligence company spun out of King's College London. It uses AI-powered hyperspectral imaging to assess tissue condition in real time during surgery. Its HYPERSNAP system has received UK certification and FDA clearance.

Series A · $23M · 2026-05

Scopia Surgical (also referred to as Scopia Tech) is a Montreal, Canada-based surgical navigation company founded in 2024 by CEO Gabriel Rivest and CTO Sébastien Delorme. It builds an AI surgical navigation software platform that fuses real-time spatial intelligence with patient-specific digital twins generated from CT/MRI scans — positioned as "a GPS for minimally invasive robotic surgery" — for gynaecologic, urologic and colorectal procedures, integrating into existing surgical workflows without additional tracking hardware. The roughly seven-person team is backed by Quebec innovation bodies including MAIN, Centech ETS and Medteq+.

Pre-Seed · $3M · 2026-09

Founded in 2010 in Singapore, Biobot develops surgical robotics systems. Its flagship product Mona Lisa is an FDA-cleared, CE-marked prostate surgery robot with over 20,000 procedures completed and more than 50 units installed worldwide.

Series B · $24M · 2024-03

Founded in 2023 in Ramat Gan, Israel, CustoMED uses AI and 3D printing to generate patient-specific orthopedic surgical tools and implants.

Seed · $6M · 2025-11